Activiomics
Curated by SignalPhosphoproteomic solutions for biomarker discovery and drug development.
Overview
Activiomics provides phospohoproteomic solutions for biomarker discovery and drug development. Its platform technology TIQAS (Target Quantification of Cell Signaling) is a software package that enables the quantification of phosphopeptides. The company uses a protease to break down the cell tissues into peptide fragments and then applies a combination of mass spectroscopy and TIQAS for identification of biomarkers. In March 2014, Activiomics was acquired by Retroscreen (now hVivo) for 4M GBP.
Key facts
- Founded
- 2009
- Headquarters
- London, United Kingdom
- Stage
- Sign up to view
- Industry
- Health Technology
Contact
- Primary office
- Sign up to view